Disclosed are an intracellular antibody (intrabody) and a preparation method and a use thereof. The intrabody includes a fragment of the variable region of the heavy chain (VH) of a monoclonal antibody that recognizes mutant huntingtin (mHTT) and a signal sequence of lysosome-associated membrane protein I (LAMP1). The VH fragment includes an amino acid sequence as shown in any one of SEQ. ID NO. 1-3. The intrabody described in this application possesses a bidirectional recognition function, enabling it to bind to and recognize mHTTs as well as specifically recognize lysosomes, thereby realizing the targeted degradation of mutant proteins and improving the degradation efficiency of the mutant proteins.

The invention relates to the identification of a highly stable single domain antibody scaffold (hs2d Ab) and its use in generating synthetic single domain antibody library (hs2d Ab-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.

The present disclosure relates to compositions and methods for using cells having cellular immunotherapies comprising a composition of chimeric antigen receptor (CAR)-modified CD4+ T cells and a composition of CD8+ T cells modified with a distinct CAR in that the intracellular signaling component of the each CAR is different, wherein the modified CD4+ and CD8+ T cells have enhanced helper and effector functions, respectively, and together more effectively augment the immune response. Such cellular immunotherapies are useful in treating disease, such as cancer.

The present invention relates to a method for the mass-production of exosome comprising a cargo protein, a vector for preparing the exosome, exosome including a cargo protein prepared by the method, and a method for loading the cargo protein to cytosol by using the exosome prepared thereby. According to the method for preparing an exosome comprising a cargo protein provided by the present invention, the exosome loaded with a cargo protein can be produced with a high yield, so that it can be used broadly in the treatment of disease using the exosome.

The present disclosure provides intrabody compositions comprising i) an intrabody and ii) one or more inserts. The disclosure also provides methods for activating and deactivating intracellular and extracellular interactions utilizing the compositions, for instance via chemical and/or light.

The present invention provides a method for producing an exosome that transfers an active substance specifically to a target and the exosome produced by the same; a method for delivering the active substance to the target tissue using the exosome; a pharmaceutical composition for delivery of the active substance comprising the exosome as an active ingredient; and a composition for preparing the exosome comprising an expression vector wherein the target peptide is inserted into an extracellular portion of a transmembrane protein.

The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

Compositions and methods of use are provided for intrabodies that bind and alter the effects of poly-glutamate protein aggregation in poly-glutamate associated diseases, such as in Huntington's disease. Intrabodies are provided that prevent poly-glutamate aggregation, gene dysregulation, and negative effects of Huntington's disease.

The invention relates to protein-based T-cell receptor knockdown, and its use in T-cell therapies.

This invention provides compositions and methods to prevent aberrant cell proliferation in a subject using a single-domain antibody (sdAb) directed against an intracellular component, wherein the aberrant cell proliferation can be cancer. The sdAb is synergistic with one or more chemotherapeutic drugs and improves therapeutic efficacy of the one or more chemotherapeutic drug against cancer. The invention also includes a method of treating viral infections using a single-domain antibody (sdAb), wherein the sbAb inhibits the replication of Ebola viruses and Zika viruses in infected cells.